Employees: 1,461
Size Orchid Pharma (ORCHPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $613M, the 776th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹955.95 on 18 Nov 2026.
Performance Over six months the shares gained 29.9%, against -26.6% for the median peer and +3.8% for the India market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 10.8% over the last twelve months (peer median +4.6%); the operating margin is 0.3% (peer median 4.4%).
Valuation It trades at 83.1× forward earnings against a peer median of 10.8× (most expensive of 7).
Capital Return on invested capital runs 19.0 points below its cost of capital (19.1% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹9.43B | ₹12.3B | ₹13.9B | ₹8.19B | ₹6.66B |
| Revenue growth | — | -12% | +70% | +23% | — |
| Gross profit | ₹1.76B | ₹867M | ₹1.98B | ₹1.36B | ₹707M |
| EBITDA | ₹410M | ₹462M | ₹1.48B | ₹1.11B | ₹845M |
| Net income | ₹86.7M | ₹99.6M | ₹1.35B | ₹922M | ₹463M |
| Free cash flow | n/a | -₹2.62B | -₹940M | ₹568M | -₹983M |
| Capital expenditure | n/a | ₹3.90B | ₹1.54B | ₹648M | ₹849M |
| Total debt | n/a | ₹3.07B | ₹1.54B | ₹2.04B | ₹4.00B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ORCHPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.0% | -10.7% | 2nd highest of 20 |
| 6-month return | +29.9% | -26.6% | highest of 20 |
| Distance from 52-week high | -16.4% | -41.0% | 2nd highest of 20 |
| Revenue growth (TTM) | +10.8% | +4.6% | 6th highest of 16 |
| Operating margin | 0.3% | 4.4% | 6th lowest of 15 |
| Forward P/E | 83.1× | 10.8× | most expensive of 7 |
| ROIC minus cost of capital | -19.0 pp | -3.9 pp | 2nd lowest of 14 |
| Net debt / EBITDA | 5.5× | 0.1× | most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | n/a | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 11.4× | -6.6% | +5.4% |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 79.7× | 9.1% | +7.9% |